Abstract:The tumor microenvironment (TME) is a critical determinant in the initiation, progression, and treatment outcomes of various cancers. Comprising of cancer‐associated fibroblasts (CAF), immune cells, blood vessels, and signaling molecules, the TME is often likened to the soil supporting the seed (tumor). Among its constituents, tumor‐associated macrophages (TAMs) play a pivotal role, exhibiting a dual nature as both promoters and inhibitors of tumor growth. This review explores the intricate relationship between TAMs and the TME, emphasizing their diverse functions, from phagocytosis and tissue repair to modulating immune responses. The plasticity of TAMs is highlighted, showcasing their ability to adopt either protumorigenic or anti‐tumorigenic phenotypes based on environmental cues. In the context of cancer, TAMs' pro‐tumorigenic activities include promoting angiogenesis, inhibiting immune responses, and fostering metastasis. The manuscript delves into therapeutic strategies targeting TAMs, emphasizing the challenges faced in depleting or inhibiting TAMs due to their multifaceted roles. The focus shifts towards reprogramming TAMs to an anti‐tumorigenic M1‐like phenotype, exploring interventions such as interferons, immune checkpoint inhibitors, and small molecule modulators. Noteworthy advancements include the use of CSF1R inhibitors, CD40 agonists, and CD47 blockade, demonstrating promising results in preclinical and clinical settings. A significant section is dedicated to Chimeric Antigen Receptor (CAR) technology in macrophages (CAR‐M cells). While CAR‐T cells have shown success in hematological malignancies, their efficacy in solid tumors has been limited. CAR‐M cells, engineered to infiltrate solid tumors, are presented as a potential breakthrough, with a focus on their development, challenges, and promising outcomes. The manuscript concludes with the exploration of third‐generation CAR‐M technology, offering insight into in‐vivo reprogramming and nonviral vector approaches. In conclusion, understanding the complex and dynamic role of TAMs in cancer is crucial for developing effective therapeutic strategies. While early‐stage TAM‐targeted therapies show promise, further extensive research and larger clinical trials are warranted to optimize their targeting and improve overall cancer treatment outcomes.

Leveraging macrophage metabolism for anticancer therapy: opportunities and pitfalls

Metabolic reprogramming of macrophages in cancer therapy

Metabolism and macrophages in the tumor microenvironment

The role of macrophages in the tumor microenvironment and tumor metabolism

Metabolic reprograming of tumor-associated macrophages

Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy

Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities

Metabolic reprogramming in the immunosuppression of tumor-associated macrophages

Metabolism, metabolites, and macrophages in cancer

A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells

Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy

Leveraging macrophages for cancer theranostics

Modulation of macrophage metabolism as an emerging immunotherapy strategy for cancer

Tumor‐associated macrophages: A sentinel of innate immune system in tumor microenvironment gone haywire

Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy

Regulation of intrinsic and extrinsic metabolic pathways in tumour-associated macrophages

The Role of Metabolic Plasticity of Tumor-Associated Macrophages in Shaping the Tumor Microenvironment Immunity

From monocyte‐derived macrophages to resident macrophages—how metabolism leads their way in cancer

Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing

Reprogramming of tumor-associated macrophages by metabolites generated from tumor microenvironment

Targeting macrophages: therapeutic approaches in cancer